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Abstract
The objectives were to test the null hypotheses that (1) citrate, maltolate, and
fluoride do not significantly influence oral Al bioavailability, Cmax or Tmax at an Al
dose relevant to drinking water exposure; and (2) Al citrate and maltolate are
absorbed intact from the gastrointestinal tract. Male Fisher rats were given 1 ml of
solution intra-gastrically containing 1 nCi 26Al (65 nmol total Al) as the Al3+ ion, or
as complexes with 14C-citrate, 14C–maltolate or fluoride, during concurrent 27Al iv
infusion. Blood was repeatedly collected for serum 26Al, total Al and 14C
quantification. Absorption parameters were estimated using WinNonlin. Al
bioavailability, Cmax and Tmax from the ion, citrate, maltolate, and fluoride were 0.29
± 0.11, 0.61 ± 0.31, 0.50 ± 0.25, and 0.35 ± 0.10%; 659 ± 195, 1073 ± 250, 881 ±
356, and 880 ± 295 fg/ml; and 1.2 ± 0.9, 1.0 ± 1.1, 1.3 ± 1.0, and 1.0 ± 0.9 h (X ±
SD) respectively. Serum 14C was ~100 times higher than 26Al. The results suggest
a non-significant enhancement of oral Al bioavailability by citrate and maltolate,
some Al complex dissociation in the GI tract, and less absorption of Al than citrate
or maltolate. The presence of citrate, maltolate and fluoride, at a similar molar
concentration to Al, would not be expected to greatly influence Al absorption from
drinking water.

Keywords: Accelerator mass spectrometry, aluminum bioavailability, 26Al, 14C,
chemical species

Abbreviations:
Al

aluminum

AMS

accelerator mass spectrometry

Cmax

maximum blood concentration
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cta

citrate

ETAAS

electrothermal atomic absorption spectrometry

malt

maltolate

Tmax

time after dosing of Cmax

4

Introduction
Aluminum (Al) has no demonstrated essential function in mammals. It is a
neurotoxicant. It has been suggested that Al is associated with Alzheimer’s disease,
although this is controversial [1]. In patients receiving renal dialysis, Al can cause
dialysis encephalopathy, renal osteodystrophy and a hypochromic microcytic
anemia [2]. Experiments with rats and mice demonstrated embryo/fetal toxicity
after oral administration of a variety of Al salts [3, 4].
Various Al compounds have been used to study Al toxicity, including Al
chloride and nitrate salts, and Al complexes with citrate, fluoride, lactate, and
maltolate [5]. Little attention was paid to Al speciation in most studies. There is
evidence that some Al species are more toxic than others. Citric acid has been
used in drinking water treatment as a membrane cleanser and as a pile/well
cleaning aid, and is present in many dietary sources such as fruit juices and soft
drinks. Al forms relatively strong complexes with citrate by binding through its
carboxyate and -hydroxyl groups [6, 7] . It has been suggested that citrate is a
major factor in the toxicity of orally administrated Al [8, 9]. Maltol (3-hydroxy-2methyl-4H-pyran-4-one), a natural product and an approved food additive in the US
and Australia, is used as a flavor enhancer in beverages like coffee and chocolate
milk and as a favoring agent in breads and cakes. At neutral pH and mM Al
concentrations, Al(maltolate)3 is soluble and stable to hydrolysis [10]. Al maltolate
was more toxic to animals and neuronal and glial cells than Al lactate or Al chloride
[10, 11]. Oral administration of Al maltolate resulted in increased brain Al [12, 13].
Fluoride is commonly present in drinking water. Al and fluoride can form stable
complexes [14]. By mimicking phosphate AlF3 and AlF4- can inhibit GTPase activity
and affect the activity of a variety of phosphoryl transfer enzymes which are
important in cell signal transduction or energy metabolism [15]. The addition of
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fluoride to i.p. injections of Al increased Al-induced behavioral toxicity [16].
Consumption of Al fluoride in drinking water by rats for 1 year resulted in increased
neuronal abnormalities [17]. These studies raised concern about the concurrent
presence of fluoride and Al in drinking water.
Major sources of Al intake include drinking water, food and medications [18].
Oral Al bioavailability from drinking water was estimated in several studies in rats
to be 0.05 to 0.36%, based on urinary Al output or Al in urine plus Al retained in
bone, liver and brain [19-21]. Oral Al bioavailability was estimated to be 0.25 to
0.4% from a comparison of areas under the curve (AUC) of serum Al concentration
versus time when Al was given po and iv [22]. Several studies showed that a high
dose of citrate enhanced Al absorption from both pharmacological and
physiological Al exposures, and at various pHs [19, 20, 23, 24]. However, none of
the previous studies determined the Al species at the exposure conditions.
Plasma citrate and Al concentrations were measured in 3 humans after oral
administration of 280 mg Al and 3.2 gm citrate [25]. The authors concluded it was
unlikely that Al was absorbed as Al citrate because plasma citrate concentrations
had returned to baseline values before the Al absorption peak occurred. However a
similar study at an Al dose relevant to drinking water has not been reported.
The only reported study that estimated oral Al bioavailability from Al
maltolate found it to be ~ 0.1% [21]. However the authors did not report the Al
species, or Al:maltolate molar ratio under the conditions studied, preventing
calculation of the Al species.
The interaction between fluoride and Al relevant to their oral absorption has
been investigated in rats and mice [26]. Co-administration of fluoride or citrate with
Al increased plasma Al levels, whereas Al decreased fluoride absorption. However
Glynn et al. concluded that fluoride (50 mg/L) did not change Al absorption, based
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on right femur Al concentration after 6 week oral exposure to 100 mg/L Al [23]. The
bioavailability of Al in the presence of fluoride at a drinking water-relevant level has
not been reported.
Accelerator mass spectrometry (AMS) is an ultra-sensitive analytical
technique that has been applied to the measurement of rare nuclides such as 26Al
and 14C, as in this study, enabling their use as tracers. AMS does not measure
radionuclide decay. It counts individual isotope atoms, making it a very efficient
technique to measure radioisotopes with long half-lives [27, 28]. It is the only
method currently available to study Al absorption and kinetics at physiological
concentrations. However, the high cost of 26Al and 14C analysis by AMS limits the
use of this experimental method.
The U.S. Environmental Protection Agency currently recommends Al in
drinking water be < 0.2 mg/L for aesthetic purposes
(http://www.epa.gov/safewater/mcl.html). Additional research on the
pharmacokinetics and toxicity of Al species in drinking water (e.g. Al fluoride) was
needed as part of the consideration for development of drinking water regulations
and guidance [29, 30]. The primary objective of the current study was to test the
hypothesis that the absolute oral bioavailability of Al in rats is the same when
dosed as the Al3+ ion in the absence of added ligands or in the presence of citrate,
maltolate, or fluoride at a dose relevant to daily consumption of Al in drinking water
by humans. 26Al and AMS were used to address this objective. Al bioavailability,
Cmax and Tmax in the absence or presence of ligands were also compared to test the
null hypothesis that these ligands do not have an effect on Al absorption. By
quantifying serum 14C by AMS following oral administration of 26Al 14C-citrate and
26Al 14C-maltolate,

the hypothesis that Al does not dissociate from citrate and

maltolate in the GI tract and is absorbed as Al complexes was also tested. The Al
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species of the administered solutions were predicted by computer modeling based
on known Al-ligand binding constants, Al hydrolysis constants, Al and ligand
concentrations, and pH. Citrate, maltolate and fluoride were selected for study as
Al ligands in the current work because of their presence in the diet and/or drinking
water and the concern that they increase Al toxicity.
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Materials and Methods
Materials
26Al

(0.5 Ci/mole, 26Al:27Al ratio = 1:34) in 0.1 N HCl was obtained from

the Purdue Rare Isotope Measurement Lab (PRIME Lab). 14C-citric acid (109
mCi/mmol) was purchased from Amersham Biosciences. 14C-maltol (50.9
mCi/mmol) was custom synthesized for this project by PerkinElmer. Sodium
fluoride, sodium hydroxide and all other chemicals were obtained from Sigma.
The solutions for oral dosing were prepared the day of their administration by
combining the Al and ligand, from stock solutions, and incubating the resulting
dosing solution for 1 h at room temperature. The pH was adjusted by addition of
dilute NaOH with stirring. The Al solution for iv infusion was prepared by
dissolving AlK(SO4)2 in saline. It was sterilized by filtration through a 0.22 µm
filter.

Animals
The subjects were 23 male Fisher 344 rats, weighing 270 ± 18 gm (X ±
SD). Animal work was approved by the University of Kentucky Institutional
Animal Care and Use Committee. The research was conducted in accordance
with the Guiding Principles in the Use of Animals in Toxicology.

Experimental procedures
All rats were implanted with two femoral venous cannulae 1 day prior to
oral dosing. This enabled iv administration through one cannula and blood
withdrawal from another. The withdrawal cannula terminated upstream of the Al
administration cannula to enable more accurate determination of the serum Al
concentration. Oral Al absorption was determined in the un-anesthetized rat.
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Systemic Al clearance was estimated in a pilot study following an iv bolus Al
injection [22]. Oral Al bioavailability was calculated by comparison of the areas
under the plasma Al concentration curves following concurrent oral and iv Al
doses, where the tracer 26Al was used in the oral dose and 27Al as the iv infusion
dose. We did not give the iv 27Al as a large bolus dose because it would produce
plasma Al concentrations in excess of the capacity of transferrin to bind Al,
resulting in Al citrate species that would probably be eliminated at a different rate
than Al transferrin. This would not model the normal species of Al in plasma,
which is > 90% Al transferrin [7]. Rather, we infused 27Al at a rate selected to
maintain a plasma Al concentration of ~ 500 ng/ml, as described [22].
Twenty-two rats received an iv infusion of 27Al at 100 µg Al/kg/h as
AlK(SO4)2 in saline from 14 h prior to 24 h after oral dosing. One rat was
randomly assigned to receive an iv infusion of saline to measure the endogenous
serum Al concentration. The 22 subjects were randomly assigned to receive 1 ml
of MilliQ-purified water or 1 ml of a solution containing 26Al (52 ng [1 nCi] 26Al and
~1700 ng 27Al, total 65 nmol Al, therefore 65 μM) by gastric administration. This
was given in the absence of ligands or in the presence of citrate, maltolate or
fluoride. The MilliQ water-dosed group had 2 rats to monitor 26Al and 14C
contamination of samples. Each Al treatment group had 5 rats. The ratio of total
Al to ligand was 1:1 for citrate (containing 30 nmol [5764 ng; 3270 nCi] 14C-citric
acid), 1:3 for maltolate (containing 30 nmol [3784 ng; 1530 nCi] of 14C-maltol)
and 1:4 for fluoride. The pH of the administered solution was adjusted to ~ 5 for
the free Al3+ ion, ~ 7 for Al in the presence of citrate or maltolate, and ~ 4 for Al in
the presence of fluoride. To assess if there was significant loss of Al due to
adsorption to the syringe or gastric feeding needle used to deliver the oral Al
solution, the oral delivery procedure was simulated by delivery of identical Al
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solutions into a plastic tube. The delivered Al concentration was compared to the
solution for delivery. The delivered solutions of the Al ion, citrate, maltolate and
fluoride, contained 104, 92, 97 and 107% of the Al concentration of the original
solution, showing no significant adsorption loss of Al to the syringe or feeding
needle.
Al speciation in the solutions prepared for gastric administration was
calculated from pH 2 to 8 using the computer modeling program SPECIES
(Academic Software, Trimble, Otley, UK). Values for the aluminum hydrolysis
constants were taken from [31], the solubility constant for freshly prepared
Al(OH)3 from [32], Al citrate binding constants from [7], Al maltolate binding
constants from [33], and the Al fluoride constants from [34]. The presence of
insoluble Al, presumably amorphous Al(OH)3, was determined by Al analysis in
dosing solutions (without 26Al addition) before and after passage though a 0.22
μm filter. The unfiltered and filtered solutions, and the concentrated Al stock
solution from which they were prepared, were analyzed by electrothermal atomic
absorption spectrometry (ETAAS) to determine their Al concentration.
Blood was withdrawn 1 h prior to, and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 4, 8
and 24 h after oral dosing. The blood withdrawn, 0.4 ml in the first 9 samples,
then 0.6 and 2.2 ml in the 8 and 24 h samples, respectively, was replaced by an
equal volume of injected saline. Serum was obtained for quantification of total Al,
26Al,

and 14C. Blood urea nitrogen (BUN) and creatinine were determined in the

24 h sample to assess renal function. When the BUN or creatinine was above the
normal limit (30 mg/dl or 1 mg/dl, respectively), the rat was replaced with another
rat.
The absence of food in the stomach was produced by limiting food
access to a 10% protein diet that was designed to minimize gastric food retention
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(Harlan Teklad 95215). This diet was available from 08:00 to 18:00 h daily for 7
days prior to gastric 26Al dosing. Food and water were removed 14 h before to 4
h after dosing and a fecal collection cup, modified from [35], was installed to
prevent fecal recycling. In a pilot study, six rats had access to this diet for 10 h
daily for 7 days. Fourteen h after diet removal, no food or feces were found in
their stomachs [22].

Analysis of total Al by electrothermal atomic absorption spectrometry (ETAAS)
Al was quantified by ETAAS, using a Perkin–Elmer 4100 ZL spectrometer.
Serum samples were diluted ten-fold with 0.2% HNO3 containing 2.5 mM Mg as a
matrix modifier, and compared to Al aqueous standards in the same matrix. All
serum samples were repeatedly analyzed until their determined total Al
concentration RSD was <10%.

Analysis of 26Al and 14C by accelerator mass spectrometry (AMS)
Quality control serum samples containing 26Al were prepared by po
administration of Al (52 ng 26Al and 1700 ng 27Al, total 65 nmol Al) to 2 rats. Blood
was collected at 4 h. Quality control serum samples containing 14C were
prepared by po administration of citric acid containing 30 nmol 14C-citrate given
with equimolar 27Al. Blood was collected at 2 h.
Samples were prepared for AMS of 26Al as described [22]. Four mg 27Al
(ICP/DCP standard, Aldrich) was added to a 100 μl aliquot of each serum sample
(except 200 μl for 8 h and 1000 μl for 24 h sample) to enable determination of the
26Al:27Al

ratio by AMS and quantification of serum 26Al by its comparison to the

known (4 mg added) 27Al concentration. The sample was dried overnight at 80° C,
digested in 2 ml of a 70:30 mixture of HNO3 and H2O2, heated at 80 °C to
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evaporate the liquid, which was trapped, the residue dissolved in 0.5 ml 35%
nitric acid and transferred to a porcelain crucible, dried overnight and ashed at
1000 °C for 2 hr. The radionuclide (26Al) to stable nuclide (27Al) ratio was
determined by the PRIME Lab [36].
For 14C sample processing and analysis, 50 µl serum samples frozen in
micro-centrifuge tubes were sent to the PRIME Lab. The production of graphite
for 14C analysis included lyophilization, combustion and graphitization [37].
One quality control sample containing 26Al or 14C was processed with
each batch of serum samples to assess the accuracy and precision of the
analysis. Five 26Al replicate quality control serum samples had a RSD of 3.8%.
Five 14C replicate quality control serum samples had a RSD of 4.9%. Samples
analyzed for 26Al or 14C with a normalized radionuclide/stable nuclide percent
error > 10% or 20%, respectively, were not included in the data analysis.

Data analysis
Pharmacokinetic analysis of the 26Al serum results was conducted using
WinNonlin. One and two compartment models were used to best fit the 26Al data
to estimate AUC, Cmax and Tmax. The mean total Al serum concentration was
calculated from the AUC of total Al divided by the time period -1 h to 24 h. Oral
26Al

bioavailability was calculated from the following:

AUC for 26Al × 27Al infusion rate
Mean total Al serum concentration × 26Al dose

13

Statistical analysis
The results were tested for normality of distribution using the KolmogorovSmirnov test and for equal variances using Bartlett’s test for the 26Al results (four
treatments) and F test for 14C results (two treatments). A one-way ANOVA was
conducted to test for significant treatment differences of absolute Al
bioavailability, Cmax, and Tmax among the 4 Al species. The square root
transforms of the 26Al bioavailability results were similarly compared. Results
are expressed as X ± SD. Significance was accepted at P < 0.05.
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Results
The Al species in the freshly prepared solutions for intragastric
administration, predicted by calculations, are shown in Figure 1. The dotted lines
in Figure 1 denote solutions that would be supersaturated with respect to the
precipitation of amorphous Al(OH)3, based on the solubility product of freshly
prepared aluminum hydroxide [32].
In the absence of added ligands, the speciation of the Al3+ ion is
dominated by hydrolysis reactions. A 65 µM solution of Al at pH 5 consists of
comparable amounts of Al3+ and Al(OH)2+, with a smaller concentration of
Al(OH)2+. A neutral solution of a 1:1 mixture of Al and citrate consists primarily of
the trimer Al3(H-1cta)3(OH)4- and ~ 20% of the Al(H-1cta)- monomer. In these
formulas, cta3- refers to the citrate anion in which all three carboxylate groups are
deprotonated, and H-1cta4- refers to a coordinated ligand in which the α-hydroxyl
group has also been deprotonated as a result of metal binding. The Al fluoride
solution at pH 4 consists of ~ 55% AlF2+, 40% AlF3, 4% AlF2+, and 1.7% AlF4-.
The speciation calculations indicate that the Al would be fully soluble in the Al ion,
Al citrate and Al fluoride administered solutions.
The speciation results for the administered Al maltol solution show a
mixture at pH 7 of 64% Al(mal)3, 25% Al(OH)3, ~ 5% Al(OH)4- and ~ 5% Al(mal)2+.
Although the calculated Al(OH)3 concentration exceeds the solubility of freshly
prepared Al(OH)3, no visible precipitate was observed. It appears that in these
dilute solutions, either the formation of insoluble Al(OH)3 is too slow to be
observed during the one hour incubation time between their preparation and
delivery, or the total mass of the precipitate is too small to be detected visually.
Neutralization of a 10 mM Al3+ solution to pH 7 led to the formation of colloidal
particles of Al(OH)3 with a diameter of ~ 400 nm, which resulted in only a faint
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opalescence, rather than an obvious precipitate [32]. Such colloids remain labile
and reactive for at least 30 min following neutralization [38]. True equilibration of
Al solutions with the less soluble, crystalline form of Al(OH)3 (gibbsite) takes
months [39]. Thus any Al present in the dosage solutions as the nominally
insoluble Al(OH)3 remained dispersed in solution as a labile, colloidal suspension.
The Al in such colloids, if not absorbed directly, would remain bioavailable to
some degree due to the ability of the colloid to equilibrate with chelating agents
as the solution conditions change.
The Al concentration determined by ETAAS in the unfiltered and filtered
Al citrate (pH 7), Al maltolate (pH 7) and Al fluoride (pH 4) solutions at 20, 65,
and 200 µM and 2 mM Al was not greatly different from that expected, based on
the Al concentration in the solution from which these simulated dosing solutions
were prepared. At 65 µM Al, the Al concentration in the unfiltered Al citrate,
maltolate and fluoride solutions was 105, 86 and 96%; and in the filtered
solutions 91, 86 and 92% of expected, respectively. For citrate and fluoride, the
similarity between the results for filtered and unfiltered solutions is consistent with
the speciation calculations that indicate that the free Al concentration is below the
solubility limit for amorphous Al(OH)3 formation. In the case of maltol, the
similarity between the filtered and unfiltered samples shows that any colloidal
Al(OH)3 has a small particle size, which supports the hypothesis that the Al within
these colloids is capable of equilibrating relatively quickly with the solution as
conditions change.
At pH 7, in the absence of ligand, the Al concentration in the 20, 65, and
200 µM and 2 mM Al conditions was 11, 13, 51 and 52% in the unfiltered and 10,
4, 1.5 and 1.5% in the filtered solutions, as expected if significant Al hydroxide is
present, as predicted by the results shown in Figure 1, Panel A. For 65 µM Al at
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pH 5, only 50% of Al passed through the 0.22 µM filter, even though the
speciation results do not predict a significant amount of precipitation at this pH.
This discrepancy could reflect some error in the experimental KSP for freshly
precipitated Al(OH)3.
The BUN and serum creatinine values of the rats ranged from 3.9 to 17.8
mg/dl and 0.2 to 0.5 mg/dl, respectively, and were within normal limits. Therefore
data from all subjects were used in the analysis.
26Al

in all serum samples was determined by AMS with an analytical error

of ≤ 10%. There were 7 14C serum samples with an analytical error > 20%; they
were not included in the data analysis. Since these samples were from 7 different
rats, this did not greatly influence the data analysis. All results had a normal
distribution with the exception of the Tmax values for 26Al. The variances did not
differ among/between treatment groups with the exception of the Cmax values for
14C

(p = 0.028).
The average 26Al concentration in the serum samples obtained from all

rats prior to 26Al dosing was 0.71 ± 0.76 fg/ml (X ± SD, range = 0 to 3.27 fg/ml).
The 26Al concentration in serum samples from non-26Al treated rats was 1.07 ±
1.16 fg/ml (range = 0 to 4.64 fg/ml). The peak serum 26Al concentration after oral
26Al

dosing was ≥ 70 times the 26Al concentration in serum from non-26Al-dosed

rats. For both 14C-citrate and 14C-maltol, the peak 14C concentration after the oral
14C

dose was ≥ 30 times that seen in non-14C-dosed rats. The total serum Al

concentration in the rat that did not receive the 27Al infusion was ~ 50 ng/ml. The
mean total serum Al concentration in the rats that did receive the 27Al infusion
was 639 ± 168 ng/ml. The time courses of serum 26Al concentration following oral
26Al

dosing are shown in Figure 2. Absolute bioavailability, Cmax and Tmax values

for 26Al are shown in Table 1. Although the mean oral bioavailability and Cmax of
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Al as the citrate, maltolate and fluoride was 2.1, 1.7 and 1.2 and 1.6, 1.3 and 1.3
times higher than in the absence of ligands, respectively, no statistically
significant differences were observed among these 4 Al species. The time
courses of serum 26Al and 14C after Al citrate and Al maltolate administration, as
a percentage of the administered dose per ml serum, are shown in Figure 3. The
shapes of the serum 14C and 26Al concentration versus time curves for individual
rats were similar, although serum 14C was ~100-fold higher than serum 26Al. 26Al
and 14C concentrations returned close to the baseline by 24 h.
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Discussion
The current study tested the following null hypotheses: 1) citrate, maltolate,
and fluoride do not influence Al bioavailability, Cmax or Tmax at an Al dose relevant to
human consumption of Al in drinking water; 2) Al citrate and maltolate complexes
do not dissociate in the GI tract and are absorbed intact.
The Al dose given in this study was similar to the daily oral Al intake from
water by humans. Humans consume an average of 1.4 L per day of drinking
water [40] containing 50 to 100 µg (1.85 to 3.7 mol) Al/L [41]. This yields a
typical daily oral Al intake of ~ 0.14 mg, (2 µg/kg for a 70 kg human). The rats (~
300 g) were dosed with 1 ml of 65 µM Al (5.85 µg/kg b.w.). Given the rat surface
area of ~ 425 cm2 and human surface area of ~18,000 cm2, the dosage of Al to
the rats was ~ 0.0041 µg/cm2, about 1/2 of the human daily Al exposure from
drinking water (~ 0.0078 µg/cm2).
The molar ratio of Al to ligands was as employed in Al transport and
uptake studies in Caco-2 cells [42]. Species calculations show that at pH 7 nearly
all of the citrate and ~ 70% of the maltolate should be bound to Al in the prepared
dose solutions. In the rat stomach pH (~ 3.2) [43] there would be significant
dissociation of Al maltol and Al citrate to produce mixtures containing higher
concentrations of the free ligand and unchelated Al3+ ion. As the pH increases
from the stomach to the rat jejunum (~ 7) [44] Al complexes with citrate and
maltol would form again. The Al-F complexes remain largely intact at the pH of
the stomach, but would be expected to convert to Al-hydroxo complexes at the
neutral pH of the jejunum. The absence of food and feces in the stomach, and
probably upper intestine, at the time of dosing enabled us to test the hypothesis
that Al maltol and Al citrate were absorbed intact. If the Al citrate complex was
absorbed intact, the time course and extent of absorption of 26Al and 14C-citrate
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should be comparable. Our results suggested considerable dissociation of the Al
citrate complex in the GI tract.
The average fluoride concentration in drinking water, obtained from
surface water, was 0.1-0.3 mg/L (5.5-15.8 µM)
(http://sfwater.org/detail.cfm/MC_ID/13/MSC_ID/166/MTO_ID/299/C_ID/1456/Lis
tID/1). Fluoride is often added to the “optimal’ level of ~ 0.7 mg/L (36.8 µM) to
prevent tooth decay (http://www.fluoridation.com/enviro.htm). We studied an Al:F
ratio = 4 because 1) almost all Al binds to F- under this condition and 2) the ratio
is close to the Al:F ratio in non-fluoridated drinking water.
The administration of two isotopes of Al (26Al and 27Al) and the much
greater iv administration of 27Al made it possible to concurrently determine the
AUCs of oral and iv Al administration in the same subject. This approach reduced
inter-subject variability when calculating absolute bioavailability. It is possible that
the elevated concentration of Al in the blood from the iv infusion could influence GI
tract Al absorption, but there are no reports suggesting this. Recent literature
relevant to the mechanism(s) of Al absorption from the GI tract suggests roles for
passive paracellular diffusion between cells and active transport. As the Al
concentration in the delivered oral solution (~ 1755 ng/ml) exceeded the plasma Al
concentration, the elevated blood Al would not be expected to significantly inhibit
paracellular diffusion of Al. The transferrin metal binding capacity for Al was not
saturated under this condition, suggesting elevated blood Al would not affect
speciation of the absorbed 26Al.
A disadvantage of the use of 26Al as a tracer is the high cost of its
analysis by AMS, which limits the experimental design to a small number of
samples. For substances that have very low oral bioavailability, such as Al, it is
difficult to detect small differences in the percentage absorbed without a fairly
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large number of subjects, especially in the presence of considerable variability. In
the current study, although the mean Al bioavailability in the presence of citrate
was 2-fold of that in the absence of ligands, these differences were not
statistically significant. Based on the results of the mean and SD of Al
bioavailability, the power of these results is 0.42, 0.30 and 0.12 for the Al ion
group compared to the Al citrate, Al maltolate and Al fluoride groups, respectively,
at a significance level of 0.05, using (http://calculators.stat.ucla.edu/powercalc/).
To increase the power to 0.9 to see a significant difference between these 2
groups, at least 6 and 16 rats, 11 and 23 rats, and 69 and 63 rats would be
required for the Al ion and Al citrate groups, Al ion and Al maltolate groups, and
Al ion and Al fluoride groups, respectively. Even though the bioavailabilities for
these Al complexes were not statistically significantly different, their differences
might be relevant. Bioequivalence is a term in pharmacokinetics generally used
to assess the expected in vivo biological equivalence of two proprietary
preparations of a drug (http://en.wikipedia.org/wiki/Bioequivalence). If two
products are said to be bioequivalent it means that they have the same
bioavailability and potency, assuming equal doses. In the United States, FDA
considers two products bioequivalent if the 90% confidence interval of relative
bioavailability (rate and extent of availability, e.g. Cmax and AUC) of the test to
reference lie within an acceptable range (80%-125%). In the current study, the
mean Al oral bioavailability and Cmax in the presence of citrate, maltolate and
fluoride (as test product) versus the absence of ligands (as reference) were 210,
170 and 120% and 160, 130 and 130%, respectively. The relative bioavailability
and Cmax were above the upper limit 125%. Therefore, Al in the presence of
ligands failed to demonstrate bioequivalence to Al in the absence of ligands.
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The bioavailability of Al when introduced as the ion in the current study
was 0.28%, consistent with results using the same experimental methods [22]. A
2-fold increase of the mean absorption of Al in the presence of citrate was seen
compared to Al alone. Enhanced Al absorption in the presence of citrate has
been repeatedly reported from studies that used 27Al [45]. There are several
reported studies, conducted under conditions that model drinking water Al
concentration, which used 26Al to investigate the effect of citrate on Al absorption.
It was reported that the oral administration of 200 μL citrate (62 g/L) enhanced
26Al

absorption 5- to 10-fold [19]. The 26Al was given as 3.8 ng 26Al and 63 ng 27Al

(2.5 nmol total Al) at pH 1.6 to 2 and an Al to citrate molar ratio of 1:25,000.
Concomitant intake of 1 mmol of citrate (molar Al to citrate ratio = 1:40,000; 3.8
ng of 26Al and 63 ng of 27Al, 2.5 nmol total Al) increased median Al absorption by
about 2- to 5-fold [20]. However in another study conducted under the same
conditions, no significant enhancement by citrate was seen [46]. In these 3
studies, where a high citrate to Al ratio (Al:citrate = 1:25,000 or 1:40,000) was
used, Al absorption increased 2- to 10-fold. In the current study, a much lower
citrate dose (65 nmol) and Al:citrate ratio (1:1) were used. The effect of citrate on
Al absorption was not statistically significant. Increasing the citrate to Al ratio
would favor formation of a smaller 1:2 Al:citrate complex (Al(H-1cta)(cta)4-), which
might more easily diffuse through the paracellular pathway than the Al3(H1cta)3(OH)

4-

trimer formed at lower citrate:Al ratios. The absorption of Al, when

administered as the citrate (5 ng of 26Al and 80 ng of 27Al, 3.1 nmol total Al, pH
6.2, citrate dose not reported), was greater than when Al hydroxide was given
(2.7 ng of 26Al and 43.2 ng 27Al, 1.7 nmol total Al, pH 7), 0.7 versus 0.1% [21].
When 1 mmol/kg sodium citrate was added to 12.1 ng of 26Al as Al citrate at pH =
8.3 (Al:citrate 1:40,000), Al absorption increased to 5%. Based on the speciation
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model used to prepare Figure 1, we would predict that such a large excess of
citrate would completely suppress the formation of the Al-citrate trimer and that
essentially 100% of the Al would be the 1:2 Al(H-1cta)(cta)4- complex.
The overall results of the previous studies and current study suggest the
effect of citrate on Al absorption might be citrate dose dependent. This is
consistent with results using Caco-2 cells where citrate had a different effect on the
flux of 2 μM versus 8 mM Al-citrate. 2 μM citrate did not have a significant effect on
Al flux whereas at 8 mM Al-citrate, the citrate affected tight junction integrity to
influence Al flux [42]. In previous rat studies, the high dose of citrate (65 to 100
μmol in most 26Al rat studies) may have interacted with the GI tract to facilitate Al
absorption by the paracellular pathway while the much lower dose (65 nmol in the
current study) had a less obvious effect. Exposure to Al citrate resulted in markedly
enhanced transmural Al transport in vitro in duodenal and jejunal everted gut
preparations compared to Al chloride [47]. This was associated with increased
deposits in intercellular spaces of ruthenium red (a marker used to evaluate tight
junction structural integrity) and a prolonged significant reduction in transmural
resistance. Similarly, permeability of Al in the Caco-2 cell study was low,
suggesting poor oral absorbance, independent of the absence or presence of
ligands, as long as the integrity of the cell monolayer was maintained [42].
However, when tight junction permeability increased, Al flux similarly increased.
This is in agreement with the results of the current study where Al absorption was
< 1% at 65 nmol, and citrate, maltolate, and fluoride had no significant effect on Al
bioavailability, Cmax and Tmax. Administration of much larger doses of Al and citrate
has a much greater potential to change the GI milieu and produce nonphysiological absorption results. This adds to the difficulty of comparing the results
among these studies.

23

The absorption of Al when administered as the maltolate approximated that
of Al hydroxide (~ 0.1%) [21]. The Al was given as 5 ng 26Al and 80 ng 27Al, 3.1
nmol total Al, pH = 6, in 2 ml water (1.55 μm). The Al to maltolate molar ratio was
not reported. Al is present primarily as a Al(maltolate)3 complex at 65 μM Al and
195 μM maltolate at pH = 7, as in the present study, whereas at 1.55 μM Al and
4.65 μM maltolate at pH 6 virtually all the Al would be a mixture of Al(OH)2+ and
Al(OH)3. Therefore, the predominant Al species in this study might have been Al
hydroxide. In the present study, the bioavailability of Al, introduced as the maltolate,
was 0.51%. The presence of maltolate did not significantly change the
bioavailability, Cmax or Tmax of Al compared to the absence of ligands.
This is the first study to investigate the effect of fluoride on Al absorption at
a physiologically-relevant Al concentration using 26Al. Since fluoride was also
studied at a physiologically-relevant concentration, the expected increase of
fluoride in rat serum was not predicted to be discernable from endogenous fluoride.
As there is no appropriate fluoride tracer that could have been used in this study
only serum Al was measured in rats that received Al fluoride. The presence of
fluoride did not significantly change the bioavailability, Cmax or Tmax of Al.
The present study was the first to use 26Al and 14C to address the null
hypothesis that Al citrate and Al maltolate do not dissociate in the GI tract, resulting
in their absorption intact. The serum 14C concentration from oral administration of
26Al 14C-citrate

or 26Al 14C-maltolate was ~100 times higher than expected if the 14C

was absorbed as an Al-ligand complex. One interpretation is that there was
considerable dissociation of Al citrate and Al maltolate in the GI tract. As ~ 80% of
the citrate in the Al citrate dosing solution was associated with Al (Figure 1, Panel
B) the free citrate does not account for the ~ 60% absorption of 14C from 14C-citrate,
as Al bioavailability was ~ 0.6% and citrate ~ 100-fold greater. For Al maltolate,
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speciation calculations predict that ~ 35% of the Al would not be associated with
maltolate, leaving sufficient non-Al associated maltolate to account for the
absorption of 14C from 14C-maltolate. At the lower pH of the rat stomach even
though a higher percentage of Al would be associated with maltol, there would still
be sufficient free maltol to account for the observed uptake of 14C. Serum 14C
approached zero by 24 h, suggesting no free citrate or maltol remained in the
intestine available for absorption.
Serum citrate peaked after 32 min and returned to baseline by 90 min,
whereas blood Al peaked after 87 ± 19 min, then decreased slowly over 24 h in 3
humans who drank a solution containing 280 mg (10.37 mmol) 27Al, as the
hydroxide, and 3.2 g citrate (15.45 mmol) at pH = 4.5 [25]. There was 100-fold
greater citrate than Al absorption. Based on these results the authors concluded
that it was unlikely that Al was absorbed as Al citrate. The administered solutions
in this study were very concentrated; 0.1 M Al3+ and 0.17 M citrate. The authors
attempted to assess the speciation of the aluminum in the discussion of their
results. However, the model that they used included only mononuclear complexes.
Speciation calculations for these conditions using the model from the present study
indicate that about 60% of the Al would have been the trimer and about 40%
Al(cta)23-. At the more alkaline pH of the intestine, the percentage of trimer would
have increased to almost 90%. Owing to the use of 26Al and the exquisite
sensitivity of AMS, the Al dose in the present study was 0.0006% of this previous
study. In the present study, the serum 14C and 26Al peaks occurred at a similar time.
Considering that the magnitude of citrate absorption was 100 times that of Al
absorption, it is very possible that a small fraction of the absorbed citrate was as Al
citrate, e.g., the Al was absorbed as the Al citrate complex.
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The pH increase from the stomach to duodenum to jejunum is due to
carbonate and bicarbonate secretion. Although the interactions between Al and
carbonate or bicarbonate ions are so weak that they can be neglected [48], the
results of the present study suggest considerable Al dissociates from citrate. The
Tmax of Al in the present study was approximately 1 h and that of citrate ~ 2 h,
consistent with their absorption from the proximal small intestine. The nonabsorbed Al in the intestine that was freed from the ligand may have formed Al
hydroxide or associated with mucus on the wall of the GI tract to be taken up into
epithelial cells and sequestered in the cell nuclei, or excreted into feces.
In summary, the results of the current work advanced the understanding of
the importance of the chemical species of Al on its absorption from the GI tract and
the risk assessment of Al toxicity, when administered as the Al3+ ion, or as Al
citrate, maltolate or fluoride in drinking water. Generally, these results did not reject
the null hypothesis that citrate, maltolate and fluoride have no significant effect on
Al absorption (bioavailability, Cmax, and Tmax) under the studied conditions. At an Al
dose relevant to that consumed by the human in drinking water the absolute
bioavailability of Al was < 1%. Citrate and maltolate absorption were much greater
than Al. Although Al bioavailability didn’t significantly increase after a single oral
dose in the presence of citrate, maltolate or fluoride compared to the Al ion under
the conditions studied, the absorption of Al when given as the ion, citrate, maltolate
and fluoride failed to demonstrate bioequivalence. Furthermore, this study only
addressed oral bioavailability. The distribution of Al to target organs, such as the
brain, and the resulting effects, as well as the rate of clearance by the kidney
and/or the liver may not be equivalent for these Al species. Further study of the
effect of ligands on Al absorption, distribution and elimination under conditions that
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model Al consumption in drinking water during long term exposure is needed for a
more informed risk assessment of Al.
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Figure legends
Figure 1. Results of Al speciation calculations at a total of 65 μM Al in the
absence of ligands (Panel A); and in the presence of citrate (cit) (65 μM) (Panel
B), maltolate (mal) (195 μM) (Panel C), and fluoride (F) (260 μM) (Panel D) in the
pH range 2 to 8. The dotted lines indicate solutions which exceed the solubility
product of freshly prepared Al(OH)3, i.e. the pH range in which the calculated
concentration of Al(OH)3 exceeds its solubility.

Figure 2. Time courses of serum 26Al concentrations following oral administration
of 52 ng 26Al in the absence of ligands or in the presence of citrate, maltolate or
fluoride. Values are mean ± SD from the 5 rats of each Al treatment group. The X
axis is shown in three segments to expand the results from the early time points.

Figure 3. Serum 26Al and 14C in each of the five rats after oral administration of
26Al-14C-citrate

(upper five panels) and 26Al-14C-maltolate (lower five panels),

shown as a percentage of the administered dose/ml serum. Serum 26Al shown
as squares and dashed line with the scale on the left axis. Serum 14C shown as
triangles and solid line with the scale on the right axis. Each panel shows results
from one rat with a connecting line among the points. Note the 100-fold
difference in the Y scales on all graphs.
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Table 1. The absolute oral bioavailability (non-transformed and square root
transformed), Cmax, and Tmax of 26Al administered in the absence of ligands (ion) or
in the presence of citrate, maltolate or fluoride, and Cmax, and Tmax of 14C from
citrate and maltolate.

ANOVA or
Ion

Citrate

Maltolate

Fluoride

t-test
result

26Al

oral bioavailability (%) 0.29 ± 0.11 0.61 ± 0.31 0.50 ± 0.25 0.35 ± 0.10

p = 0.11

26Al

oral bioavailability (%) (square root transform)

p = 0.14

26Al

Cmax (fg/ml)

659 ± 195

1073 ± 250

881 ± 356

880 ± 295

p = 0.18

26Al

Tmax (h)

1.2 ± 0.9

1.0 ± 1.1

1.3 ± 1.0

1.0 ± 0.9

p = 0.90

14C

Cmax (ng/ml)

1.8 ± 0.7

0.6 ± 0.2

p = 0.0059

14C

Tmax (h)

2.9 ± 2.2

1.2 ± 1.1

p = 0.15
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